Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene

J Invest Dermatol. 2010 Jan;130(1):314-6. doi: 10.1038/jid.2009.197.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Drug Resistance, Neoplasm / genetics
  • Female
  • Humans
  • Imatinib Mesylate
  • Melanoma / drug therapy*
  • Melanoma / genetics
  • Middle Aged
  • Piperazines / therapeutic use*
  • Point Mutation
  • Proto-Oncogene Proteins c-kit / genetics*
  • Pyrimidines / therapeutic use*
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / genetics

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Proto-Oncogene Proteins c-kit